Announcing the new issue of Prime’s managed care report, featuring the latest trends and updates in medical and pharmacy benefits - Prime Therapeutics
Announcing the new issue of Prime’s managed care report, featuring the latest trends and updates in medical and pharmacy benefits
Prime Therapeutics Report shares more about single-treatment gene therapies and proper management
Prime Therapeutics (Prime) today launched the spring edition of the Prime Therapeutics Report, featuring timely topics such as single-treatment gene therapies and value-based contracting to address the dynamic growth trend and cost of gene and cell therapies. The triannual Magellan Rx Report provides an in-depth analysis of trends associated with high-cost, innovative therapies and the latest updates to inform our clients’ coverage and benefit decisions.
The Prime Therapeutics Report spring edition includes expert commentary on the following topics:
- Single-treatment gene therapies and proper management
- Myasthenia gravis treatment advances and associated payer impact
- Ophthalmic update on new treatment options and management strategies
- Tumor biomarkers in breast cancer – ESR1 testing and targeted therapies
- Product spotlight: Leqembi for Alzheimer’s disease
- Update on new FDA-approved biosimilars
- Pipeline drug list update
Download a copy of the report to go deeper into these timely trends.
Stay current on ways Prime is reimagining pharmacy management to provide the same care we would want for our loved ones.
About Prime Therapeutics
Prime Therapeutics LLC (Prime) is a diversified pharmacy solutions organization. We offer innovative pharmacy benefit management, specialty and medical drug management, and state government solutions to millions of people across the country. At Prime, we’re reimagining pharmacy solutions to provide the care we’d want for our loved ones. We challenge the way it’s always been done to develop intelligently designed solutions that deliver savings, simplicity and support to help people achieve better health. For more information, visit us at PrimeTherapeutics.com or follow us on LinkedIn.